The pharmaceutical company Reig Jofre, a member of CATALONIA.HEALTH, has signed a commercial agreement with LEO Pharma, with the aim to strengthen the promotion of LEO Pharma’s innovative treatment for mild to moderate psoriasis within the scope of Primary Care in Spain.
Asabys Partners, a member of CATALONIA.HEALTH, has announced that its investee Augustine Therapeutics, has closed a Series A financing round, raising a total of 85 million dollars.
i4KIDS, the Paediatric Innovation Hub at Sant Joan de Déu Barcelona Children's Hospital, member of CATALONIA.HEALTH, has been awarded the National Award for Knowledge Transfer Promotion 2024 by the Catalan Foundation for Research and Innovation (FCRI) and the Government of Catalonia.
The technological company Neos Surgery, a member of CATALONIA.HEALTH, has received the Innovation Award at the VIII edition of the Spanish SME of the Year Award 2024, held in Madrid.
The gene therapy biotechnology company SpliceBio, a member of CATALONIA.HEALTH, announced that it has dosed the first patient in the Phase 1/2 ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector, for the treatment of Stargardt disease.
The health sector plays a key role in the digital world we live in. That is why digital health has had an important place at the 2025 edition of 4YFN, the event parallel to the Mobile World Congress (MWC), which is a benchmark for the international entrepreneurial ecosystem, and that is why CATALONIA.HEALTH was there to showcase examples of the best local medical device technologies. CATALONIA.HEALTH successfully met a new challenge, as it participated in this event for the first time.
The biotech company CONNECTA Therapeutics, a member of CATALONIA.HEALTH, has announced positive results from its Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics profile of its drug candidate CTH120 in adult volunteers.
The biotech company Ona Therapeutics, a member of CATALONIA.HEALTH, announced key leadership appointments in their leadership team to support its rapid growth and pipeline advancement.
The DeepTech company Devshealth’s CEO Alfons Nonell-Canals, member of CATALONIA.HEALTH, has been elected as a member of the BEAM Alliance Board of Directors during the recent AMR conference.
The pharmaceutical company Reig Jofre, a member of CATALONIA.HEALTH, reinforces its dermatology business with the launch of Vincobiosis® Acneic, an innovative range of topical products that blend science and nature to effectively and gently manage acne-prone skin.
The advanced therapeutics company Integra Therapeutics moves its headquarters to the new Advanced Therapies Platform at SJD Barcelona Children's Hospital, both members of CATALONIA.HEALTH.
The Vall d’Hebron Research Institute (VHIR), a member of CATALONIA.HEALTH, has implemented a new innovation model to reshape how biomedical research impacts society.
The biotech company Zymvol, a member of CATALONIA.HEALTH, has raised a seed funding of €3M. It was led by venture capital firms Faber Ventures (lead investor), Elaia Partners (existing pre-seed investor), and Übermorgen Ventures.
The Hospital Sant Joan de Déu Barcelona and Oxolife have received the CATALONIA.HEALTH 2025 Award (formerly Bioèxit) during the 11th edition of the Nit, the annual event of reference in the field of health and life sciences in Catalonia, organised by CATALONIA.HEALTH and life sciences in Catalonia, organised by CATALONIA.HEALTH. The award recognises relevant trajectories and projects based on the axes of innovation, science and business, and which stand out for their excellence in areas such as scientific innovation, industrialization innovation, industrialisation, regulatory milestones and international expansion.
CATALONIA.HEALTH has repeated its collaboration with Tech Spirit Barcelona, the annual event promoted by Tech Barcelona, which showcases the city's up-and-coming technology scene. This year's edition once again brought together medical professionals, health technologists, pharmaceutical leaders and entrepreneurs in a dynamic convergence of innovators who are redefining the landscape of healthcare delivery and accessibility, demonstrating the drive for change in the future of healthcare.
Laboratorios Rubió, a CataloniaBio & HealthTech member, will market a non-invasive test to detect non-alcoholic fatty liver and related diseases. The new test is called OWLiver® and has been developed by the biotech firm OWL.
OWLiver® is precise, non-invasive and cheaper than other techniques such as ultrasound or magnetic resonance. OWLiver® is based on the lipidomic analysis of the patients’ blood serum.
With this agreement for Spain and Latin America, Laboratorios Rubió has strengthened its position in the field of in vitro diagnostics (IVD) and metabolomics.
Do you want to know more Laboratorios Rubió? We recommend this video of CataloniaBioHT interviewing them:
Cookies settings
We collect and process your personal information for the following purposes: Analytics, Security & Marketing.
Comments